Novo Nordisk shares plummet as 2025 guidance is cut, overshadowing new CEO
Novo Nordisk, holder of one of the largest market capitalisations in Europe, warned that full-year sales growth was expected to be 8% to 14%, a steep climbdown from its already-cut May forecast of 13% to 21%.
Shares in the Danish drugmaker dropped a sizeable 21.7% to DKK346.9 at market close on 29 July following the announcement. Shares rallied by only 2% on 30 July at market open, representing a subdued new day opening. The share plunge wiped more than €60bn ($69bn) from the company's value.
The stock's drift on the Copenhagen stock exchange nearly overshadowed Novo Nordisk's appointment of a new CEO. It was confirmed that Maziar Mike Doustdar, currently Novo's EVP of international operations, will take the helm of the metabolic disease specialist. He succeeds Lars Fruergaard Jørgensen, who parted ways with Novo in May amid concern that the company was falling behind rivals in the weight loss market. Share price in Novo has been gradually declining since late 2024 due to competition in the metabolic disease space.
Doustdar will have his work cut out to restore Novo to its perch in the glucagon-like peptide 1 receptor agonists (GLP-1RA) market. Eli Lilly has taken a lead with sales for tirzepatide, in part due to its higher efficacy. Analysis by GlobalData in January 2025 demonstrated that tirzepatide was outpacing semaglutide in the obesity market, the former having a higher sale ceiling forecast by 2031. Last year, Eli Lilly's sales grew 32% compared to 26% for Novo Nordisk.
Novo Nordisk blamed lower growth expectations for Wegovy in the US obesity market for its cut 2025 guidance. Lower growth expectations for diabetes drug Ozempic in the US GLP-1RA market was also highlighted, as well as lower-than-expected penetration for Wegovy in international markets.
Lower sales have not solely been caused by Eli Lilly – the rise in compounded semaglutide has eroded market share for Novo Nordisk. These alternatives were cheaper and more accessible for patients, the competition forcing Novo to cut the price of Wegovy in the US. The company has maintained that continued compounding is unlawful and unsafe.
'For Wegovy in the US, the sales outlook reflects the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition,' Novo Nordisk said in a statement.
A further blow was dealt earlier this week after a Delaware court ruled that patents for a weight loss drug manufactured by Viatris, currently awaiting approval from the US Food and Drug Administration (FDA), do not infringe on Wegovy.
Doustdar, who joined Novo in 1992, is not the only executive change happening at the company. The drugmaker is merging early R&D and development into a single unit. Martin Holst Lange, currently EVP of development, will become chief scientific officer on 7 August. Doustdar will assume the role of CEO on the same date.
The CEO-to-be said in his first statement: 'I come to this role with a sense of urgency, a laser focus on high performance, and a fierce determination for Novo Nordisk to aim higher than it's ever done, and to deliver to many more patients the innovation they need.'
"Novo Nordisk shares plummet as 2025 guidance is cut, overshadowing new CEO" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Koninklijke Heijmans' (AMS:HEIJM) Performance Is Even Better Than Its Earnings Suggest
Koninklijke Heijmans N.V.'s (AMS:HEIJM) earnings announcement last week was disappointing for investors, despite the decent profit numbers. We did some digging and actually think they are being unnecessarily pessimistic. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Examining Cashflow Against Koninklijke Heijmans' Earnings One key financial ratio used to measure how well a company converts its profit to free cash flow (FCF) is the accrual ratio. The accrual ratio subtracts the FCF from the profit for a given period, and divides the result by the average operating assets of the company over that time. The ratio shows us how much a company's profit exceeds its FCF. That means a negative accrual ratio is a good thing, because it shows that the company is bringing in more free cash flow than its profit would suggest. While having an accrual ratio above zero is of little concern, we do think it's worth noting when a company has a relatively high accrual ratio. Notably, there is some academic evidence that suggests that a high accrual ratio is a bad sign for near-term profits, generally speaking. Koninklijke Heijmans has an accrual ratio of -0.21 for the year to June 2025. That indicates that its free cash flow quite significantly exceeded its statutory profit. In fact, it had free cash flow of €199m in the last year, which was a lot more than its statutory profit of €112.0m. Koninklijke Heijmans' free cash flow improved over the last year, which is generally good to see. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Our Take On Koninklijke Heijmans' Profit Performance As we discussed above, Koninklijke Heijmans' accrual ratio indicates strong conversion of profit to free cash flow, which is a positive for the company. Based on this observation, we consider it possible that Koninklijke Heijmans' statutory profit actually understates its earnings potential! And the EPS is up 28% annually, over the last three years. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. If you'd like to know more about Koninklijke Heijmans as a business, it's important to be aware of any risks it's facing. Case in point: We've spotted 1 warning sign for Koninklijke Heijmans you should be aware of. This note has only looked at a single factor that sheds light on the nature of Koninklijke Heijmans' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 minutes ago
- Yahoo
Here's why I'm batty about Games Workshop, 1 of the FTSE's best growth shares
Games Workshop (LSE:GAW) released another extraordinary trading update on Tuesday (29 July), sending its shares close to recent record peaks. Long-term investors like me have learned to expect the unexpected from the fantasy wargaming specialist. But bat-related news probably wasn't on anyone's bingo card, and is probably a first for the London stock market. In a footnote to its update, the FTSE 100 company drew special attention to 'the cute looking pipistrelle bat that is delaying our work on our new temporary car park'. Animal lovers needn't be alarmed, by the way–Games Workshop added that 'we are carefully looking after the bat'. Aside from that nature update, there were some other unexpected things for shareholders to digest, too. Both revenues and pre-tax profits came in ahead of City forecasts, at £617.5m and £262.8m, respectively, in the financial year to May 2025. The company had forecast figures of at least £610m and £255m two months ago. And it sent Games Workshop's share price close to June's all-time high of £167.30. Profits powerhouse This week's update underlines why Games Workshop is one of my favourite FTSE 100 growth shares. It just keeps delivering outstanding trading performances, even when economic conditions are tough and consumer spending power fades. Sales were up 18% year on year in 2025, while pre-tax profit increased 30%. Earnings per share, meanwhile, also increased 30% to 594.9p per share. The company's products — spearheaded by the famous Warhammer 40,000 sci-fi franchise — are in high demand at all points of the economic cycle. Their quality and brand power provides an economic moat that supports strong revenues growth even during broader market downturns. These advantages also mean Games Workshop enjoys the luxury of world-class margins. Last year, the core gross margin rose 10 basis points year on year to 69.5%. This fatty percentage gave the bottom line another substantial boost. Licence to grow It's great to see the company's box sets, paints, and other game-related products continue flying off the shelves. But what's got me especially excited is the rate at which licensing revenues are growing. While sales across its core operations rose a healthy 14% last year, licencing revenue growth of 69% was truly outstanding. This reflected forecast-beating sales of its Space Marine 2 video game. Games Workshop is sitting on a goldmine of intellectual property (IP), and is ramping up partnerships and licensing deals with media producers to capitalise on it and turbocharge long-term growth. Financial 2025's strong numbers bode well, with Space Marine 3 in the works and Amazon starting work on a Warhammer 40,000 film and TV series. A top FTSE share Annual earnings have risen 34% on average at Games Workshop over the last decade. And I'm confident it will keep delivering spectacular yearly growth over the long term. There are some dangers it must navigate, though, such as rising protectionism in key markets. It has warned that trade tariffs will wipe £12m off pre-tax profits this year alone. Rising competition is another danger to sales and margins. But I'm hopeful it will still keep delivering stunning returns, underpinned by its dominant market position and those ambitious licencing plans. The post Here's why I'm batty about Games Workshop, 1 of the FTSE's best growth shares appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Royston Wild has positions in Games Workshop Group Plc. The Motley Fool UK has recommended Amazon and Games Workshop Group Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025
Yahoo
11 minutes ago
- Yahoo
PSI Software Second Quarter 2025 Earnings: €0.11 loss per share (vs €0.40 loss in 2Q 2024)
PSI Software (ETR:PSAN) Second Quarter 2025 Results Key Financial Results Revenue: €73.0m (up 18% from 2Q 2024). Net loss: €1.70m (loss narrowed by 73% from 2Q 2024). €0.11 loss per share (improved from €0.40 loss in 2Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period PSI Software Earnings Insights Looking ahead, revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Software industry in Germany. Performance of the German Software industry. The company's share price is broadly unchanged from a week ago. Balance Sheet Analysis While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of PSI Software's balance sheet and an in-depth analysis of the company's financial position. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
